- HOME
- About Us
- Mission & History
Mission
Broadening drug discovery research to contribute to human health
AIGENDRUG is revolutionizing the pharmaceutical development paradigm through its AI drug discovery platform, DrugVLAB, ushering in a new era in drug discovery. DrugVLAB efficiently identifies optimal drug candidates, minimizing the costs and risks associated with failure in preclinical and clinical stages. Through state-of-the-art AI drug discovery research, AIGENDRUG discovers new disease targets and develops therapies, continuously contributing to the improvement of human health.Value
-
Improving the efficiency and success rates in drug discovery
with world-class technology to overcome diseases. -
A global AI-driven drug development company creating
customized value for clients. -
A collaborative company committed to social responsibility.
-
An excellent working environment where the company
and its employees grow together.
History
2024
-
2024.06
Participate in the BioUSA 2024 -
2024.04
Launched the AI Drug Discovery Platform (DrugVLABTM)
2023
-
2023.08
Honored with the 2023 South Korea Good Enterprise Award (Outstanding R&D Award)’ -
2023.05
Obtained Venture Business certification Selected for the government-supported ‘Early-Stage Startup’ package -
2023.04
National R&D Project Selection (Rural Development Administration) Collecting database of in silico deep-data on bioactive materials
2022
-
2022.07
KPBMA, (Artificial Intelligence New Drug Development Support Center) selects a field-oriented innovative education project -
2022.06
Selected for government R&D grants (Bio & Medical Technology Development Program of the National Research Foundation) -
2022.04
Received certification as an R&D center specializing in AI drug discovery
2021
-
2021.09
Secured seed investment -
2021.08
Initiated a collaborative research project with Seoul National University (Developing AI Platform to Predict Drug Toxicity and Drug Targets) -
2021.06
Established AIGENDRUG Co., Ltd.